Publisher's Synopsis
This publication contains the proceedings of a symposium focusing on carboplatin, a second-generation platinum compound that serves as a valuable example of the analog's potential for reducing toxicity while retaining the efficacy of the parent drug. Several papers examine the status of carboplatin as it is currently used in the treatment of a broad range of malignancies, including ovarian cancer, small-cell and nonsmall-cell lung cancer, head and neck cancer, urothelial and hematologic cancers. In addition, promising strategies for the future such as stem cell support, combination therapies incorporating new oncologic agents and alternative dosing regimens are discussed. While the role of carboplatin in cancer management has yet to be fully defined, the clinical data provided in this issue clearly illustrate that the value of this chemotherapeutic option is beyond doubt.
